Takeda receives FDA approval for Orzeyful, first orexin agonist to treat all symptoms of narcolepsy type 1

Takeda announced that the U.S. Food and Drug Administration has approved its drug oveporexton, which will be marketed under the name Orzeyful, for the treatment of narcolepsy type 1 in adults.

The approval marks the debut of an orexin‑2 receptor agonist on the market and is the first therapy to target the full spectrum of narcolepsy symptoms rather than isolated aspects of the disorder.

Analysts note that the drug joins existing once‑daily options such as Lumryz and Wakix, but its distinct mechanism could shift how clinicians approach the disease. The clearance is limited to adult patients at this stage.

Orzeyful is expected to become available later this year after it completes the required scheduling process with the U.S. Drug Enforcement Administration.